The Regeneron chief executive has backed an attempt by US regulators to block Amgen’s $28bn acquisition of Horizon Therapeutics as he accused some pharmaceutical companies of abusing their market power to prevent competition.
醫藥公司再生元(Regeneron)執行長支持美國監管機構阻止安進(Amgen)以280億美元收購Horizon Therapeutics的企圖。他指責一些製藥公司濫用市場力量，阻礙競爭。
您已閱讀7%（322字），剩餘93%（4150字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。